The role of blood Inc-ZFAS1 in acute ischemic stroke: correlation with neurological impairment, inflammation, and survival profiles

Gang Wang1 | Ying Zhou2 | Tingting Zhong1 | Aixia Song1 | Qian Xue1

Abstract

**Background:** Long non-coding RNA zinc finger antisense 1 (Inc-ZFAS1) has been reported to inhibit neuronal damage in acute ischemic stroke (AIS). However, the role of Inc-ZFAS1 in AIS patients remains unclear. Therefore, we assessed the relationship of Inc-ZFAS1 with neurological impairment, inflammation, and prognosis in AIS patients.

**Methods:** Totally, 241 AIS patients and 120 controls were enrolled. Inc-ZFAS1 in peripheral blood mononuclear cells was evaluated using reverse transcription-quantitative polymerase chain reaction. Besides, a 3-year follow-up was conducted to assess recurrence-free survival (RFS) and overall survival (OS) in AIS patients.

**Results:** Inc-ZFAS1 was reduced in AIS patients compared to that in controls ($Z = -10.693$, $p < 0.001$). In AIS patients, Inc-ZFAS1 was negatively correlated with National Institutes of Health Stroke Scale score ($r_s = -0.335$, $p < 0.001$), C-reactive protein ($r_s = -0.284$, $p < 0.001$), tumor necrosis factor-alpha ($r_s = -0.293$, $p < 0.001$), interleukin-1β ($r_s = -0.149$, $p = 0.021$), and interleukin-6 ($r_s = -0.161$, $p = 0.012$), but not underlying diseases (all $p > 0.05$). Besides, Inc-ZFAS1 was divided into high and low levels based on the median expression in AIS patients. Indeed, high Inc-ZFAS1 predicted better RFS ($\chi^2 = 6.222$, $p = 0.013$); the 1-year, 2-year, and 3-year RFS rates were 94.2%, 88.3%, and 85.5%, respectively, in patients with high Inc-ZFAS1, then 87.5%, 79.2%, and 71.6%, respectively, in those with low Inc-ZFAS1. However, Inc-ZFAS1 was not correlated with OS ($\chi^2 = 1.404$, $p = 0.236$); the 1-year, 2-year, and 3-year OS rates were 98.3%, 95.8%, and 94.0%, respectively, in patients with high Inc-ZFAS1, then 96.7%, 93.9%, and 89.6%, respectively, in those with low Inc-ZFAS1.

**Conclusion:** Lower Inc-ZFAS1 expression is connected with increased neurological impairment and inflammation as well as worse RFS in AIS patients.

**Keywords**

acute ischemic stroke, inflammation, Inc-ZFAS1, neurological impairment, recurrence-free survival
INTRODUCTION

Stroke, a cerebrovascular disease, is divided into ischemic and hemorrhagic stroke.1–3 Statistically, the overall incidence of first-ever stroke and mortality rate was 345.1 and 159.2 per 100 000 person-years in China.4 Acute ischemic stroke (AIS), the most common type, is mainly attributable to diverse risk factors, such as hypertension, diabetes, hypercholesterolemia, and smoking.5,6 AIS may lead to disability due to ischemia-induced injury and the death of neuronal cells.7,8 Although advancement in the identification of risk factors and intravascular interventional therapy improves the survival rate of patients,9,10 the prognosis of patients with AIS is still unsatisfactory, with a high relapse rate of 14.8% within 5 years.11 Therefore, finding more potential predictors for early identification of AIS in patients with a high risk of relapse and enhancing management to improve their prognosis is crucial.

Long non-coding RNAs (lncRNAs) are involved in different cellular and biological processes12,13; thus, they play important roles in diverse complex diseases, including neurological diseases.14–18 Several lncRNAs have been reported to exert protective roles, such as IncRNA metastasis associated with lung adenocarcinoma transcript 1 (MALAT1), N1LR, and Macpl.14–18 Recently, it has been shown that IncRNA zinc finger antisense 1 (ZFAS1) alleviates neuronal inflammation and injury in AIS. For example, the overexpression of IncRNA ZFAS1 attenuates oxygen and glucose deprivation-mediated injury in an AIS cell model.19 Additionally, IncRNA ZFAS1 alleviates neuronal damage through suppressing inflammation, oxidative stress, apoptosis, and nitric oxide level in an AIS animal model.20 Regarding its clinical role in AIS, IncRNA ZFAS1 could be used as a noninvasive biomarker for the diagnosis of large-artery atherosclerosis stroke patients.21 However, the relationship of IncRNA ZFAS1 with disease risk, inflammation, disease severity, and prognosis of patients with AIS remains unclear.

Therefore, the present study assessed circulating lncRNA ZFAS1 expression in AIS patients, then aimed to illustrate the relationship of lncRNA ZFAS1 with neurological impairment, inflammation, recurrence-free survival (RFS), and overall survival (OS) of patients with AIS.

METHODS

2.1 | Participants

From January 2015 to August 2018, 241 patients with first-episode AIS were consecutively recruited as the study population and 120 patients at high risk of stroke as controls. The recruitment criteria for AIS patients included: (a) diagnosis of AIS based on clinical manifestation and imaging examination; (b) at least 18 years of age; (c) admitted to the hospital within 12 h after the episode of symptoms; and (d) patients or their guardians agreed to participation in the study. The exclusion criteria were as follows: (a) concomitant hematological malignancies or cerebral tumor; (b) use of immunosuppressant within 1 month before enrollment; (c) severe infection within 1 month; and (d) pregnant or breast-feeding women. The controls were screened from populations at high risk of stroke, but without a history of stroke, and they were required to have two or more stroke risk factors, including smoking, hypertension, hyperlipidemia, hyperuricemia, diabetes mellitus, and chronic kidney disease. Additionally, at enrollment, the age of controls was limited in a range of 50–80 years, and the sex ratio was set to 3:2 (male:female), which was aimed at matching the age and gender of controls to the recruited AIS patients. The exclusion criteria for AIS patients were also applicable to the controls. The present study was approved by the Ethics Committee of the First Affiliated Hospital of Hebei North University.

2.2 | Clinical feature recording and blood sampling

Demographic information and comorbidities of the participants were documented after recruitment. The National Institutes of Health Stroke Scale (NIHSS) was employed to evaluate neurological impairment in AIS patients within 24 h (the higher the NIHSS score, the more severe the nerve damage). Peripheral blood (PB) was drawn from all participants on the day of enrollment. The PB samples from patients with AIS were divided into two parts: one was used to isolate the PB mononuclear cells (PBMCs) using density gradient centrifugation in the presence of polysucrose (Ficoll)-Urografin solution, and the other was centrifuged at 1000 g for 10 min to separate serum samples. For the controls, PBMCs were separated from PB using the same procedures. The samples were stored in liquid nitrogen following separation.

2.3 | LncRNA ZFAS1 determination

The PBMCs were subjected to quantitative analysis of lncRNA ZFAS1 expression using real-time reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The PureZOL RNA isolation reagent (Catelog#732-6890, Bio-Rad, Hercules, CA, USA) was used for total RNA extraction. The iScript cDNA Synthesis Kit (Catelog#170-8890, Bio-Rad, Hercules, CA, USA) was used for complementary DNA (cDNA) synthesis. Then, RT-qPCR was performed using the ABI Applied Biosystems 7500 PCR System (Nanjing Junwei Biotechnology Co., LTD, Nanjing, Jiangsu, China) with the QuantTa Nova SYBR Green PCR Kit (Catelog#208054, Qiagen, Duesseldorf, Nordrhein-Westfalen, Germany), where the parameters were set as follows: PCR initial activation step for 2 min at 95 °C; two-step cycling: denaturation for 5 sec at 95 °C, and combined annealing/extension for 10 sec at 60 °C. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) used as an internal reference. The primers applied in the qPCR were constructed according to the previous study.20 The relative expression of lncRNA ZFAS1 was calculated using $2^{-\Delta\Delta Ct}$ methodology.22
2.4 | Inflammatory cytokine measurement

Enzyme-linked immunosorbent assay (ELISA) with the quantitative sandwich enzyme immunoassay technique was employed to measure the inflammatory cytokines present in the serum of AIS patients, including tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and IL-6. The Human TNF-α Quantikine ELISA (Catalog#DTA00D), Human IL-1β Quantikine ELISA (Catalog#DLB50), and Human IL-6 Quantikine ELISA (Catalog#D6050) Kits were purchased from R&D Systems (Minneapolis, MN, USA). The assay was performed according to the manufacturer's instructions.

2.5 | Follow-up

For the surveillance of stroke recurrence, all AIS patients were advised to undergo reexamination every 3 to 6 months or as clinically indicated. Follow-up examinations for patients were scheduled for a total of 36 months, and the last follow-up was conducted on August 31, 2021. RFS was calculated from the first hospitalization to the first stroke recurrence or death. OS was calculated from the first hospitalization to death. Patients who were lost to follow-up were processed as censored data.

2.6 | Statistical analysis

Analysis of differences between groups was performed using the Chi-square test, Student's t-test, or Wilcoxon rank-sum test. Correlation analysis between variables was checked using the Spearman rank test or Wilcoxon rank-sum test. In the correlation analysis of lncRNA ZFAS1 expression with RFS and OS, patients were categorized into high- and low-expression groups based on the median expression value (0.417) of lncRNA ZFAS1 in AIS patients. Kaplan-Meier curves were employed to display RFS and OS, which were analyzed using the log-rank test. A two-sided P-value less than 0.05 (p > 0.05) was set to define statistical significance. SPSS 26.0 (IBM Corp., Armonk, New York, USA) and GraphPad Prism 6.01 (GraphPad Software Inc., San Diego, CA, USA) were used for analysis and plotting.

3 | RESULTS

3.1 | Study flow

In total, 279 AIS patients were screened for the current study, while 38 patients were excluded, including 21 patients for inclusion or exclusion criteria and 17 patients/guardians who declined participation. Thus, 241 patients were included in the study, and their PBMCs and serum were isolated from the blood samples. Next, the level of lncRNA ZFAS1 in PBMCs was evaluated using RT-qPCR, and the levels of TNF-α, IL-1β, and IL-6 in serum were assessed using ELISA. During follow-up examinations, the following was noted: 17 events happened within the 1st year, including 7 patients who experienced recurrences, 6 patients who died, and 4 patients who were lost to follow-up; 40 events happened within the 2nd year, including 8 patients who suffered from recurrences, 6 patients who died, and 26 patients who were lost to follow-up; and 54 events happened within the 3rd year, including 33 patients who underwent recurrences, 6 patients who died, and 15 patients who were lost to follow-up. All patients were included in the intention-to-treat analysis. The RFS and OS of patients were processed as censored data if they were lost to follow-up (Figure 1).

3.2 | Characteristics of participants

AIS patients showed a mean age of 65.9 ± 9.4 years with 71 (29.5%) females and 170 (70.5%) males; the controls had a mean age of 64.5 ± 8.1 years with 48 (40.0%) females and 72 (60.0%) males. No difference in demographic characteristics (age, sex, body mass index (BMI), and history of smoking) was observed between AIS patients and controls (all p > 0.05). However, the percentage of patients with hypertension (p = 0.045) and hyperuricemia (p = 0.002), as well as the number of risk factors (p < 0.001), were higher in AIS patients than in controls. In AIS patients, the NIHSS score was 10.1 ± 4.9; the median (interquartile range [IQR]) values of C-reactive protein (CRP), TNF-α, IL-1β, and IL-6 were 14.8 (9.3–23.9) mg/L, 71.5 (56.4–95.6) pg/ml, 2.6 (2.0–3.8) pg/ml, and 37.9 (30.0–50.0) pg/ml, respectively. Other clinical features of the participants are presented in Table 1.

3.3 | Linkage of lncRNA ZFAS1 with AIS risk

LncRNA ZFAS1 expression was lower in AIS patients than in controls (Z = −10.693, p < 0.001) (Figure 2A). Furthermore, the receiver-operating characteristic (ROC) curve showed that lncRNA ZFAS1 presented good value in identifying the risk of AIS with an area under the curve (AUC) of 0.845 (95% confidence interval [CI]: 0.802–0.888) (Figure 2B).

3.4 | Correlation of lncRNA ZFAS1 with underlying diseases in AIS patients

There was no association shown between lncRNA ZFAS1 and hypertension (Z = −1.655, p = 0.098), hyperlipidemia (Z = −1.688, p = 0.091), hyperuricemia (Z = −0.873, p = 0.383), diabetes mellitus (Z = −0.772, p = 0.440), or chronic kidney disease (Z = −1.867, p = 0.062) (Figure 3A-E).
3.5 | Correlation of lncRNA ZFAS1 with neurological impairment in AIS patients

The relationship between lncRNA ZFAS1 and NIHSS score in AIS patients is shown in Figure 4, which shows that lower lncRNA ZFAS1 expression was linked with higher NIHSS score ($r_s = -0.335, p < 0.001$), which reflects a higher level of neurological impairment.

3.6 | Correlation of lncRNA ZFAS1 with inflammation in AIS patients

lncRNA ZFAS1 expression was negatively associated with the levels of CRP ($r_s = -0.284, p < 0.001$), TNF-α ($r_s = -0.293, p < 0.001$), IL-1β ($r_s = -0.149, p = 0.021$), and IL-6 ($r_s = -0.161, p = 0.012$) (Figure 5A-D).

3.7 | Correlation of lncRNA ZFAS1 with prognosis in AIS patients

Low lncRNA ZFAS1 expression was associated with worse RFS ($\chi^2 = 6.222, p = 0.013$). Additionally, the 1-year, 2-year, and 3-year RFS rates were 87.5%, 79.2%, and 71.6%, respectively, in AIS patients with low lncRNA ZFAS1 expression, and 94.2%, 88.3%, and 85.5%, respectively, in AIS patients with high lncRNA ZFAS1 expression (Figure 6A). However, lncRNA ZFAS1 expression was not associated with OS ($\chi^2 = 1.404, p = 0.236$). The 1-year, 2-year, and 3-year OS rates were 96.7%, 93.9%, and 89.6%, respectively, in AIS patients with low lncRNA ZFAS1 expression, and 98.3%, 95.8%, and 94.0%, respectively, in AIS patients with high lncRNA ZFAS1 expression (Figure 6B).

Multivariate Cox’s proportional hazards demonstrated that lncRNA ZFAS1 (high vs. low) was an independent risk factor for RFS ($p = 0.042, HR = 0.506$), but not for OS ($p = 0.428, HR = 0.645$) in AIS patients (Table S1).
DISCUSSION

The role of lncRNA ZFAS1 in neurological diseases has gained wide attention. For instance, a study has shown that lncRNA ZFAS1 mediates spinal cord injury by binding to microRNA (miR)-1953 and regulating the phosphatase and tensin homolog (PTEN)/phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) pathway.23 Silencing lncRNA ZFAS1 regulates the recovery of neurological function in traumatic brain injury.24 In the AIS cell model, lncRNA ZFAS1 attenuates cell damage by upregulating pro-survival protein myeloid cell leukemia-1 (MCL-1) by sponging miR-186-5p.19 However, the relationship between lncRNA ZFAS1 expression, disease risk, and neurological impairment in AIS patients is still not fully understood.

### TABLE 1 Characteristics of AIS patients and controls

| Items                                      | Controls (N = 120) | AIS patients (N = 241) | Statistic (t/χ²/Z) | p value |
|--------------------------------------------|--------------------|------------------------|--------------------|---------|
| Demographics                               |                    |                        |                    |         |
| Age (years), mean ± SD                     | 64.5 ± 8.1         | 65.9 ± 9.4             | −1.442             | 0.150   |
| Gender, n (%)                              |                    |                        |                    |         |
| Female                                     | 48 (40.0)          | 71 (29.5)              | 3.564              | 0.059   |
| Male                                       | 72 (60.0)          | 170 (70.5)             |                    |         |
| BMI (kg/m²), mean ± SD                     | 23.7 ± 3.0         | 24.2 ± 2.5             | −1.568             | 0.118   |
| History of smoke, n (%)                    | 57 (47.5)          | 129 (53.5)             | 1.165              | 0.280   |
| Underlying diseases                        |                    |                        |                    |         |
| Hypertension, n (%)                        | 93 (77.5)          | 207 (85.9)             | 4.018              | 0.045   |
| Hyperlipidemia, n (%)                      | 64 (53.3)          | 117 (48.5)             | 0.734              | 0.392   |
| Hyperuricemia, n (%)                       | 31 (25.8)          | 103 (42.7)             | 9.809              | 0.002   |
| Diabetes mellitus, n (%)                   | 17 (14.2)          | 52 (21.6)              | 2.845              | 0.092   |
| Chronic kidney disease, n (%)              | 14 (11.7)          | 43 (17.8)              | 2.298              | 0.130   |
| No. of risk factors, mean ± SD             | 2.3 ± 0.5          | 2.7 ± 0.9              | −5.386             | <0.001  |
| Disease features                           |                    |                        |                    |         |
| NIHSS score, mean ± SD                     |                    | 10.1 ± 4.9             |                    |         |
| CRP (mg/L), median (IQR)                   |                    | 14.8 (9.3–23.9)        |                    |         |
| TNF-α (pg/ml), median (IQR)                |                    | 71.5 (56.4–95.6)       |                    |         |
| IL-1β (pg/ml), median (IQR)                |                    | 2.6 (2.0–3.8)          |                    |         |
| IL-6 (pg/ml), median (IQR)                 |                    | 37.9 (30.0–50.0)       |                    |         |
| Treatment                                  |                    |                        |                    |         |
| Intravenous thrombolysis, n (%)            |                    | 24 (10.0)              |                    |         |
| Endovascular interventions + Intravenous thrombolysis, n (%) | | 217 (90.0) | | |

Abbreviations: AIS, acute ischemic stroke; BMI, body mass index; CRP, C-reactive protein; IL-1β, interleukin-1beta; IL-6, interleukin 6; IQR, interquartile range; NIHSS, National Institute Health of Stroke Scale; SD, standard deviation; TNF-α, tumor necrosis factor alpha.

FIGURE 2 Long non-coding RNA zinc finger antisense 1 (lncRNA ZFAS1) expression in acute ischemic stroke (AIS) patients. Comparison of lncRNA ZFAS1 expression between AIS patients and controls (A); correlation of lncRNA ZFAS1 with AIS risk (B).
In our study, the circulating lncRNA ZFAS1 expression was lower in AIS patients than in controls, and its expression could be used to distinguish AIS patients from controls. Additionally, lncRNA ZFAS1 expression was negatively correlated with NIHSS score. This may be because (1) lncRNA ZFAS1 might protect neurons against inflammation and damage caused by acute cerebral ischemia, which reduces the risk of AIS; thus, lncRNA ZFAS1 expression was lower in AIS patients; (2) lncRNA ZFAS1 might inhibit neuronal cell apoptosis through the B-cell lymphoma-2 (Bcl-2)/Bcl-2 associated x protein (Bax)/cleaved cysteine proteases (caspases)-3 pathway, which decreases the severity of neurological impairment in AIS patients; therefore, lncRNA ZFAS1 was linked with lower NIHSS score.

LncRNA ZFAS1 regulates the inflammatory response and exerts anti-inflammatory effects in diverse human diseases. For example, overexpression of lncRNA ZFAS1 decreases pro-inflammatory cytokines in sepsis-induced acute lung injury by targeting miR-193a-3p. In addition, a study focusing on AIS presents that lncRNA ZFAS1 inhibits inflammation in an animal model, while the correlation of lncRNA ZFAS1 with inflammation in AIS patients remains unclear. Our study showed that high expression of lncRNA ZFAS1 was associated with low levels of CRP, TNF-α, IL-1β, and IL-6. The explanation might be that lncRNA ZFAS1 decreases miR-582 expression and upregulates nitric oxide synthase 3 (NOS3) expression to reduce the production of pro-inflammatory cytokines, thereby alleviating inflammation in AIS patients.

The prognostic value of lncRNA ZFAS1 is a potential biomarker for prognosis in human diseases. For example, elevated lncRNA ZFAS1 is associated with poor survival in chronic heart failure patients; however, lncRNA ZFAS1 is used as a predictive factor for better prognosis in sepsis patients. The predictive value of lncRNA ZFAS1 for outcomes in AIS remains unclear. In our study, we observed that high expression of lncRNA ZFAS1 was associated with better RFS in AIS patients while no correlation was found between lncRNA ZFAS1 and OS. This result might be caused by: (1) abnormal lipid metabolism is an independent factor for AIS recurrence, while lncRNA ZFAS1 hampered the cholesterol efflux rate in an atherosclerosis cell model, showing that lncRNA ZFAS1 had a positive
WANG ET AL.

The relationship of long non-coding RNA zinc finger antisense 1 (lncRNA ZFAS1) expression with inflammation in acute ischemic stroke (AIS) patients. Association of lncRNA ZFAS1 expression with C-reactive protein (CRP) (A), tumor necrosis factor alpha (TNF-α) (B), interleukin 1β (IL-1β) (C), or IL-6 (D).

In conclusion, lncRNA ZFAS1 is downregulated, and its lower expression is associated with more severe neurological impairment, increased inflammation, and worse RFS in AIS patients; therefore, lncRNA ZFAS1 may be a potential biomarker to manage AIS patients to improve their outcomes.
ACKNOWLEDGEMENTS
This study was supported by Scientific Research Fund of Zhangjiakou (No. 2121146D).

CONFLICTS OF INTEREST
The authors have no conflicts of interest to disclose.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID
Qian Xue https://orcid.org/0000-0002-0683-3770

REFERENCES
1. Herpich F, Rincon F. Management of acute ischemic stroke. Crit Care Med. 2020;48(11):1654-1663.
2. Katan M, Luft A. Global burden of stroke. Semin Neurol. 2018;38(2):208-211.
3. Hankey GJ. Stroke. Lancet. 2017;389(10069):641-654.
4. Wang W, Jiang B, Sun H, et al. Prevalence, incidence, and mortality of stroke in China: results from a nationwide population-based survey of 480 687 adults. Circulation. 2017;135(8):759-771.
5. Li F, Yang L, Yang R, et al. Ischemic stroke in young adults of Northern China: characteristics and risk factors for recurrence. Eur Neurol. 2017;77(3-4):115-122.
6. Diener HC, Hankey GJ. Primary and secondary prevention of ischemic stroke and cerebral hemorrhage: JACC focus seminar. J Am Coll Cardiol. 2020;75(15):1804-1818.
7. Phipps MS, Cronin CA. Management of acute ischemic stroke. BMJ. 2020;368:i6983.
8. Tuo QZ, Zhang ST, Lei P. Mechanisms of neuronal cell death in ischemic stroke and their therapeutic implications. Med Res Rev. 2022;42(1):259-305.
9. Rabinstein AA. Update on treatment of acute ischemic stroke. Continuum (Minneap Minn). 2020;26(2):268-286.
10. Yokobori S, Koido Y, Shishido H, et al. Feasibility and safety of intravascular temperature management for severe heat stroke: a prospective multicenter pilot study. Crit Care Med. 2018;46(7):e670-e676.
11. Lin B, Zhang Z, Mei Y, et al. Cumulative risk of stroke recurrence over the last 10 years: a systematic review and meta-analysis. Neurol Sci. 2021;42(1):61-71.
12. Yao RW, Wang Y, Chen LL. Cellular functions of long noncoding RNAs. Nat Cell Biol. 2019;21(5):542-551.
13. Bao MH, Szeto V, Yang BB, Zhu SZ, Sun HS, Feng ZP. Long noncoding RNAs in ischemic stroke. Cell Death Dis. 2018;9(3):281.
14. Ma N, Tie C, Yu B, Zhang W, Wan J. Identifying IncRNA-miRNA-mRNA networks to investigate Alzheimer’s disease pathogenesis and therapy strategy. Aging (Albany NY). 2020;12(3):2897-2920.
15. Wang L, Cho KB, Li Y, Tao G, Xie Z, Guo B. Long noncoding RNA (IncRNA)-mediated competing endogenous RNA networks provide novel potential biomarkers and therapeutic targets for colorectal cancer. Int J Mol Sci. 2019;20(22):5758.
16. Zhang X, Tang X, Liu K, Hamblin MH, Yin KJ. Long Noncoding RNA Malat1 regulates cerebrovascular pathologies in ischemic stroke. J Neurosci. 2017;37(7):1797-1806.
17. Wu Z, Wu P, Zuo X, et al. LncRNA-N11R Enhances Neuroprotection Against Ischemic Stroke Probably by Inhibiting p53 Phosphorylation. Mol Neurobiol. 2017;54(10):7670-7685.
18. Wang Y, Luo Y, Yao Y, et al. Silencing the IncRNA Macplip in pro-inflammatory macrophages attenuates acute experimental ischemic stroke via LCP1 in mice. J Cereb Blood Flow Metab. 2020;40(4):747-759.
19. Shen B, Wang L, Xu Y, Wang H, He S. Long non-coding RNA ZFAS1 exerts a protective role to alleviate oxygen and glucose deprivation-mediated injury in ischemic stroke cell model through targeting miR-186-5p/MCL1 axis. Cytotechnology. 2021;73(4):605-617.
20. Zhang Y, Zhang Y. IncRNA ZFAS1 Improves Neuronal Injury and Inhibits Inflammation, Oxidative Stress, and Apoptosis by Sponging miR-582 and Upregulating NOS3 Expression in Cerebral Ischemia/Reperfusion Injury. Inflammation. 2020;43(4):1337-1350.
21. Wang J, Ruan J, Zhu M, et al. Predictive value of long noncoding RNA ZFAS1 in patients with ischemic stroke. Clin Exp Hypertens. 2019;41(7):615-621.
22. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(ΔΔC(T)) Method. Methods. 2001;25(4):402-408.
23. Chen Y, Wei Z, Liu J, et al. Long noncoding RNA ZFAS1 aggravates spinal cord injury by binding with miR-1953 and regulating the PTEN/PI3K/AKT pathway. Neurochem Int. 2021;147:104977.
24. Hu F, Shao L, Zhang J, Zhang H, Wen A, Zhang P. Knockdown of ZFAS1 Inhibits Hippocampal Neurons Apoptosis and Autophagy by Activating the PI3K/AKT Pathway via Up-regulating miR-421 in Epilepsy. Neurochem Res. 2020;45(10):2433-2441.
25. Feng J, Zhou Z, Feng R, Zeng C, Wei M, Hong T. Silencing long non-coding RNA zinc finger antisense 1 restricts secondary cerebral edema and neuron injuries after traumatic brain injury. Neurosci Lett. 2021;756:135958.
26. An L, Yang T, Zhong Y, Yin Y, Li W, Gao H. Molecular pathways in sepsis-induced cardiomyocyte pyroptosis: Novel finding on long non-coding RNA ZFAS1/miR-138-5p/SESN2 axis. Immunol Lett. 2021;238:47-56.
27. Tang X, Yin R, Shi H, et al. LncRNA ZFAS1 confers inflammatory responses and reduces cholesterol efflux in atherosclerosis through regulating miR-654-3p-ADAM10/RAB22A axis. Int J Cardiol. 2020;315:72-80.
28. Ye Y, Gao X, Yang N. LncRNA ZFAS1 promotes cell migration and invasion of fibroblast-like synoviocytes by suppression of miR-27a in rheumatoid arthritis. Hum Cell. 2018;31(1):14-21.
29. Jiang Y, Wang L. LncRNA ZFAS1 plays a role in regulating the inflammatory responses in sepsis-induced acute lung injury via mediating miR-193a-3p. Infect Genet Evol. 2021;92:104860.
30. Wang X, Wu Z, Qin W, et al. Long non-coding RNA ZFAS1 promotes colorectal cancer tumorigenesis and development through DDX21-POLR1B regulatory axis. Aging (Albany NY). 2020;12(22):22665-22687.
31. Wang X, Jin Q, Wang X, Chen W, Cai Z. LncRNA ZFAS1 promotes proliferation and migration and inhibits apoptosis in nasopharyngeal carcinoma via the PI3K/AKT pathway in vitro. Cancer Biomark. 2019;24(2):171-182.
32. Nie F, Yu X, Huang M, et al. Long noncoding RNA ZFAS1 promotes gastric cancer cells proliferation by epigenetically repressing KLF2 and NFKD2 expression. Oncotarget. 2017;8(24):38227-38238.
33. Chang G, Zhang W, Zhang D, Ding G. Clinical value of circulating ZFAS1 and miR-590-3p in the diagnosis and prognosis of chronic heart failure. Cardiovasc Toxicol. 2021;21(11):880-888.
34. Xu Y, Shao B. Circulating long noncoding RNA ZNFX1 antisense RNA negatively correlates with disease risk, severity, inflammatory markers, and predicts poor prognosis in sepsis patients. Med (Baltimore). 2019;98(9):e14558.
35. Cui SB, Wang TX, Liu ZW, Yan JY, Zhang K. Zinc finger protein A20 regulates the development and progression of osteoarthritis.
by affecting the activity of NF-kappaB p65. *Immunopharmacol Immunotoxicol.* 2021;43(6):713-723.

**SUPPORTING INFORMATION**

Additional supporting information may be found in the online version of the article at the publisher’s website.

**How to cite this article:** Wang G, Zhou Y, Zhong T, Song A, Xue Q. The role of blood Inc-ZFAS1 in acute ischemic stroke: Correlation with neurological impairment, inflammation, and survival profiles. *J Clin Lab Anal.* 2022;36:e24219. doi:10.1002/jcla.24219